ATE552347T1 - Oligonukleotidverbindung und verfahren zur behandlung von nidovirusinfektionen - Google Patents
Oligonukleotidverbindung und verfahren zur behandlung von nidovirusinfektionenInfo
- Publication number
- ATE552347T1 ATE552347T1 AT04815419T AT04815419T ATE552347T1 AT E552347 T1 ATE552347 T1 AT E552347T1 AT 04815419 T AT04815419 T AT 04815419T AT 04815419 T AT04815419 T AT 04815419T AT E552347 T1 ATE552347 T1 AT E552347T1
- Authority
- AT
- Austria
- Prior art keywords
- nidovirus
- compound
- infections
- treating
- oligonucleotide compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 2
- 101710163270 Nuclease Proteins 0.000 abstract 1
- 108091027544 Subgenomic mRNA Proteins 0.000 abstract 1
- 210000004102 animal cell Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 230000002103 transcriptional effect Effects 0.000 abstract 1
- 230000029812 viral genome replication Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53270103P | 2003-12-24 | 2003-12-24 | |
| US11/022,358 US20050171044A1 (en) | 2003-12-24 | 2004-12-22 | Oligonucleotide compound and method for treating nidovirus infections |
| PCT/US2004/043341 WO2005065268A2 (en) | 2003-12-24 | 2004-12-23 | Oligonucleotide compound and method for treating nidovirus infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE552347T1 true ATE552347T1 (de) | 2012-04-15 |
Family
ID=34752430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04815419T ATE552347T1 (de) | 2003-12-24 | 2004-12-23 | Oligonukleotidverbindung und verfahren zur behandlung von nidovirusinfektionen |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20050171044A1 (de) |
| EP (1) | EP1704243B1 (de) |
| AT (1) | ATE552347T1 (de) |
| AU (1) | AU2004311826B2 (de) |
| CA (1) | CA2550642C (de) |
| WO (1) | WO2005065268A2 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2500430B1 (de) | 2004-06-28 | 2017-03-08 | The University Of Western Australia | Antisense-Oligonukleotide zur Induktion von Exon-Skipping sowie Verfahren zur Verwendung davon |
| US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| WO2007030691A2 (en) * | 2005-09-08 | 2007-03-15 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| PL2735568T3 (pl) * | 2006-05-10 | 2018-02-28 | Sarepta Therapeutics, Inc. | Analogi oligonukleotydowe mające kationowe połączenia pomiędzy podjednostkami |
| US8785407B2 (en) * | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
| KR20250016146A (ko) | 2008-10-24 | 2025-02-03 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | Dmd를 위한 다중 엑손 스키핑 조성물 |
| KR102239374B1 (ko) | 2009-11-12 | 2021-04-14 | 더 유니버시티 오브 웨스턴 오스트레일리아 | 안티센스 분자 및 이를 이용한 질환 치료방법 |
| KR101944119B1 (ko) | 2009-11-13 | 2019-01-30 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 안티센스 항바이러스 화합물 및 인플루엔자 바이러스 감염을 치료하는 방법 |
| KR20200133284A (ko) | 2010-05-28 | 2020-11-26 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| US8198429B2 (en) | 2010-08-09 | 2012-06-12 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| WO2012031243A2 (en) | 2010-09-03 | 2012-03-08 | Avi Biopharma, Inc. | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS |
| CN107693797B (zh) | 2011-05-05 | 2021-05-11 | 萨勒普塔医疗公司 | 肽寡核苷酸缀合物 |
| KR102142689B1 (ko) | 2011-11-18 | 2020-08-10 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트 |
| CN105378081B (zh) | 2013-03-14 | 2019-06-14 | 萨勒普塔医疗公司 | 用于治疗肌营养不良的外显子跳跃组合物 |
| EP3662912B1 (de) | 2013-03-15 | 2025-12-03 | Sarepta Therapeutics, Inc. | Verbesserte eteplirsen dosierungen zur behandlung von duchenne muskeldystrophie |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| MX391337B (es) | 2016-04-13 | 2025-03-21 | Janssen Pharmaceuticals Inc Star | Sistemas de replicón de arterivirus recombinantes y usos de estos. |
| EP3548625B1 (de) * | 2016-12-05 | 2024-06-26 | Janssen Pharmaceuticals, Inc. | Zusammensetzungen und verfahren zur erhöhung der genexpression |
| EP3555293A4 (de) | 2016-12-15 | 2020-08-12 | Meharry Medical College | Viruzide |
| IL316397A (en) | 2018-05-22 | 2024-12-01 | Ionis Pharmaceuticals Inc | Modulators of APOL1 expression |
| BR112022021562A2 (pt) * | 2020-04-23 | 2023-02-07 | The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone | Partículas interferentes terapêuticas para o coronavírus |
| WO2021226485A2 (en) * | 2020-05-08 | 2021-11-11 | Oregon State University | Antisense therapeutics for betacoronavirus treatment |
| WO2022056117A1 (en) * | 2020-09-10 | 2022-03-17 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and uses thereof |
| EP4008785A1 (de) * | 2020-12-03 | 2022-06-08 | Justus-Liebig-Universität Gießen | Zirkuläre nukleinsäuren und verwendungen davon zur beeinflussung der genomexpression und zur proliferation von coronaviren |
| US20240392393A1 (en) * | 2021-01-19 | 2024-11-28 | The Jackson Laboratory | Subgenomic RNAs for Evaluating Viral Infection |
| US20240229035A1 (en) * | 2021-04-28 | 2024-07-11 | Nippon Shinyaku Co., Ltd. | Antiviral nucleic acid |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5185444A (en) * | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| GB9510718D0 (en) * | 1995-05-26 | 1995-07-19 | Sod Conseils Rech Applic | Antisense oligonucleotides |
| US7094765B1 (en) * | 1999-01-29 | 2006-08-22 | Avi Biopharma, Inc. | Antisense restenosis composition and method |
| KR20010102992A (ko) * | 1999-01-29 | 2001-11-17 | 추후보정 | 표적 ｒｎａ를 검출하는 비-침입적 방법 |
| CA2392685C (en) * | 1999-11-29 | 2011-02-22 | Avi Biopharma, Inc. | Antisense antibacterial method and composition |
| KR20020079768A (ko) * | 2000-01-04 | 2002-10-19 | 에이브이아이 바이오파마 인코포레이티드 | 안티센스 항박테리아 세포분열 조성물 및 방법 |
| KR20020097241A (ko) * | 2000-05-04 | 2002-12-31 | 에이브이아이 바이오파마 인코포레이티드 | 스플라이스-영역 안티센스 조성물 및 방법 |
| EP3020804A1 (de) * | 2000-07-06 | 2016-05-18 | Sarepta Therapeutics, Inc. | Umwandlung der wachstumsfaktor-beta (tgf-beta) blockierungsmittelbehandelten stammzellenzusammensetzung und verfahren |
| US20030224353A1 (en) * | 2001-10-16 | 2003-12-04 | Stein David A. | Antisense antiviral agent and method for treating ssRNA viral infection |
| AU2002342057B2 (en) * | 2001-10-16 | 2009-01-22 | Avi Biopharma, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
| EP1503762A2 (de) * | 2002-05-10 | 2005-02-09 | Teva Pharmaceutical Industries Ltd. | Neue kristalline formen von gatifloxacin |
| AU2004230485B2 (en) * | 2003-04-10 | 2009-01-22 | Novartis Vaccines And Diagnostics, Inc. | The severe acute respiratory syndrome coronavirus |
| US7339051B2 (en) * | 2003-04-28 | 2008-03-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (SARS) |
| ES2351976T3 (es) * | 2003-04-29 | 2011-02-14 | Avi Biopharma, Inc. | Composiciones para mejorar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células. |
| WO2005000234A2 (en) * | 2003-06-12 | 2005-01-06 | Sars Scientific Corp. | Novel coronavirus inhibitors |
| EP1668145A4 (de) * | 2003-08-07 | 2010-03-10 | Avi Biopharma Inc | Sense-antivirusverbindung und verfahren zur behandlung einer ssrna-virusinfektion |
| DK1766012T3 (da) * | 2004-07-02 | 2011-09-19 | Avi Biopharma Inc | Antisense-antibakteriel fremgangsmåde og forbindelse |
| US8129352B2 (en) * | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| PL2735568T3 (pl) * | 2006-05-10 | 2018-02-28 | Sarepta Therapeutics, Inc. | Analogi oligonukleotydowe mające kationowe połączenia pomiędzy podjednostkami |
| US8785407B2 (en) * | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
-
2004
- 2004-12-22 US US11/022,358 patent/US20050171044A1/en not_active Abandoned
- 2004-12-23 AT AT04815419T patent/ATE552347T1/de active
- 2004-12-23 EP EP20040815419 patent/EP1704243B1/de not_active Expired - Lifetime
- 2004-12-23 AU AU2004311826A patent/AU2004311826B2/en not_active Ceased
- 2004-12-23 CA CA 2550642 patent/CA2550642C/en not_active Expired - Fee Related
- 2004-12-23 WO PCT/US2004/043341 patent/WO2005065268A2/en not_active Ceased
-
2006
- 2006-05-10 US US11/432,155 patent/US20070037763A1/en not_active Abandoned
-
2008
- 2008-04-25 US US12/109,856 patent/US8759307B2/en active Active
-
2014
- 2014-06-04 US US14/295,665 patent/US20150126722A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005065268A3 (en) | 2006-01-19 |
| CA2550642A1 (en) | 2005-07-21 |
| US20070037763A1 (en) | 2007-02-15 |
| US20150126722A1 (en) | 2015-05-07 |
| WO2005065268A2 (en) | 2005-07-21 |
| US20050171044A1 (en) | 2005-08-04 |
| CA2550642C (en) | 2013-10-22 |
| AU2004311826A1 (en) | 2005-07-21 |
| EP1704243A4 (de) | 2007-06-06 |
| EP1704243A2 (de) | 2006-09-27 |
| AU2004311826B2 (en) | 2011-04-28 |
| US8759307B2 (en) | 2014-06-24 |
| EP1704243B1 (de) | 2012-04-04 |
| US20090012280A1 (en) | 2009-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE552347T1 (de) | Oligonukleotidverbindung und verfahren zur behandlung von nidovirusinfektionen | |
| ATE491791T1 (de) | Oligonukleotidanalog und verfahren zur behandlung von flavivirusinfektionen | |
| ATE467688T1 (de) | Antivirale antisense-verbindung und verfahren zur behandlung von arenavirus-infektion | |
| ATE546456T1 (de) | Triheterocyclische verbindungen, zusammensetzungen, und verfahren zur behandlung von krebs | |
| DE60336550D1 (de) | Inhibitoren des hepatitis-c-virus | |
| EP1507791A4 (de) | Antisense-antivirusmittel und verfahren zur behandlung einer ssrna-virusinfektion | |
| ATE522532T1 (de) | Verbindungen zur behandlung von hepatitis c | |
| DE602005025751D1 (de) | Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle | |
| EA200900298A1 (ru) | Ингибиторы вируса гепатита с | |
| ATE327246T1 (de) | Hepatitis c tripeptid inhibitoren | |
| ATE494291T1 (de) | Verbindungen zur behandlung von hepatitis c | |
| ATE540116T1 (de) | Antivirale antisense-verbindungen und verfahren zur behandlung von filovirus-infektionen | |
| NO20070194L (no) | Fremgangsmater for behandling av hepatitt C | |
| NO20044808L (no) | Heterosykliske sulfonamider som er hepatitt C virus inhibitorer | |
| NO20044895L (no) | Substituerte cykloalkyl P1' hepatitt C virus inhibitorer | |
| EP1623012A4 (de) | Antisense-antivirusmittel und verfahren zur behandlung einer ssrna-virusinfektion | |
| EA201791776A1 (ru) | Замещенные циклофаны для использования при лечении инфекции вгс | |
| DE602004011255D1 (de) | Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit | |
| DK1334119T3 (da) | Sammensætninger og fremgangsmåder til modulering af RSV-infektion og -immunitet | |
| ATE498398T1 (de) | Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus | |
| EA201001748A1 (ru) | Соединения, используемые для лечения гепатита с | |
| CY1110797T1 (el) | Συνθεσεις για προληψη ελκων σε αλογα | |
| IS5956A (is) | Notkun bisfosónsýra til varnar og meðhöndlunar sýkingaferla | |
| ATE444749T1 (de) | Benzothiazolium verbindungen zur verwendung in methoden zur hemmung der no produktion und von tnf alpha und zur behandlung von coronavirus infektionen | |
| ATE491952T1 (de) | Screening auf inhibitoren des eindringens von hepatitis-c-virus |